Nintedanib Stada (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, FGFR and PDGFR—thereby reducing fibroblast activation, angiogenesis, and the deposition of scar tissue that characterises fibrotic lung disease and supports tumor growth.

The specific dose and dosing schedule are determined by the prescribing physician based on the approved indication, patient characteristics, and clinical response. Patients should follow the prescriber’s instructions exactly.

Safety data for nintedanib in pregnancy and lactation are insufficient. It is generally advised to avoid use during pregnancy and to discontinue breastfeeding while on therapy unless the benefits clearly outweigh the potential risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nintedanib differs from pirfenidone, another antifibrotic, by targeting a broader range of tyrosine kinases involved in vascular and fibroblast signaling. Both agents slow disease progression in idiopathic pulmonary fibrosis, but their safety profiles and drug‑interaction potentials vary, influencing clinician choice.

Store the product at ambient temperature, below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight and excessive heat to maintain stability.

Nintedanib Stada is taken orally, usually with food to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water and not crushed or chewed.

Serious concerns include liver enzyme elevation, severe bleeding, cardiovascular events such as myocardial infarction, and rare gastrointestinal perforations. Patients should be monitored regularly for these adverse outcomes.

Patients with active bleeding disorders, uncontrolled liver disease, severe cardiovascular disease, or known hypersensitivity to nintedanib should avoid this medication. It is also contraindicated in individuals taking strong CYP3A4 inhibitors without appropriate medical supervision.